Cyclophosphamide News and Research

RSS
Cyclophosphamide is a drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It is also used to treat some types of kidney disease in children. Cyclophosphamide attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent. Also called CTX and Cytoxan.

Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.
New findings on how OX40 activation affects T helper cells that target melanoma

New findings on how OX40 activation affects T helper cells that target melanoma

Computed tomography aids scleroderma lung disease prognosis

Computed tomography aids scleroderma lung disease prognosis

Assisted reproduction technology may increase risk of MS activity among women

Assisted reproduction technology may increase risk of MS activity among women

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Bone marrow transplants hold promise for sickle cell patients

Bone marrow transplants hold promise for sickle cell patients

Even partially matched bone marrow transplants can eliminate sickle cell disease in some patients

Even partially matched bone marrow transplants can eliminate sickle cell disease in some patients

Partially-matched bone marrow transplants can eliminate sickle cell disease in some patients

Partially-matched bone marrow transplants can eliminate sickle cell disease in some patients

Partially-matched bone marrow transplants can eliminate sickle cell disease in some patients

Partially-matched bone marrow transplants can eliminate sickle cell disease in some patients

Reduced-intensity benefits confirmed for AML cell transplantation

Reduced-intensity benefits confirmed for AML cell transplantation

MedQIA develops new software that forms the basis of Imaging Biomarker Information System

MedQIA develops new software that forms the basis of Imaging Biomarker Information System

Chemotherapy during pregnancy: an interview with Professor Sibylle Loibl

Chemotherapy during pregnancy: an interview with Professor Sibylle Loibl

Paper highlights clinical and immunological activity of immatics’ IMA901 in renal cell carcinoma

Paper highlights clinical and immunological activity of immatics’ IMA901 in renal cell carcinoma

CINJ commences enrollment in three-drug combination trial for breast cancer

CINJ commences enrollment in three-drug combination trial for breast cancer

Updated results from two clinical trials of Bruton's ibrutinib for CLL/SLL

Updated results from two clinical trials of Bruton's ibrutinib for CLL/SLL

Initial HSCT results from phase III trial on systemic sclerosis

Initial HSCT results from phase III trial on systemic sclerosis

Cyclophosphamide drug makes the bone marrow more tumor-friendly

Cyclophosphamide drug makes the bone marrow more tumor-friendly

Accentia, Johns Hopkins co-host meeting with prospective clinical trial investigators at AAN meeting

Accentia, Johns Hopkins co-host meeting with prospective clinical trial investigators at AAN meeting

Study finds subtle cognitive deficits in women treated with CMF chemotherapy

Study finds subtle cognitive deficits in women treated with CMF chemotherapy

Cancer cell communication signals may contain pieces of RNA

Cancer cell communication signals may contain pieces of RNA

Juvenile arthritis affected kids are at a high risk of cancer: Study

Juvenile arthritis affected kids are at a high risk of cancer: Study